What's encouraging, however, is that there may be more benefits with GLP-1 drugs than simply losing weight and controlling ...
Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...
Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic ...
In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...
Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced.
Arrowhead Pharma (ARWR) stock jumps as obesity drug ARO-INHBE doubles weight loss with Eli Lilly’s (LLY) GLP-1 therapy, ...
Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...
Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback